The short answer is a new drug called Lucentis, approved by the US Food and Drug Administration in June, though the drug has side effects, is extremely expensive, and is useful for only the rarer form of the disease. Macular degeneration and its new treatments were the focus of five separate articles in last week’s New England Journal of Medicine.